ANDREA PANAGGIO
Pharmacy in W Windsor Township, NJ
License number
New Jersey 28RI01791800
Issued Date
Jan 8, 1984
Expiration Date
Apr 30, 2019
Category
Pharmacy
Type
Pharmacist
Address
Address
W Windsor Township, NJ
Professional information
Pharmaceutical Compositions, Dosage Forms And Methods For Oral Administration Of Epothilones
US Patent:
6576651, Jun 10, 2003
Filed:
Jan 25, 2002
Appl. No.:
10/057390
Inventors:
Rebanta Bandyopadhyay - Portage MI
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31425
US Classification:
514365, 514183, 514450
Abstract:
The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.
Methods Of Administering Epothilone Analogs For The Treatment Of Cancer
US Patent:
6670384, Dec 30, 2003
Filed:
Jan 23, 2002
Appl. No.:
10/055653
Inventors:
Rebanta Bandyopadhyay - Portage MI
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31365
US Classification:
514365, 514183
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringers Injection.
Parenteral Formulation For Epothilone Analogs
US Patent:
7022330, Apr 4, 2006
Filed:
Jan 17, 2002
Appl. No.:
10/051727
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 9/00
US Classification:
424400, 424422, 514365, 514 37, 514183, 548146
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.
Parenteral Formulation For Epothilone Analogs
US Patent:
8632788, Jan 21, 2014
Filed:
Nov 4, 2008
Appl. No.:
12/264375
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 9/00, A61K 31/425
US Classification:
424400, 514365
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.
Pharmaceutical Compositions, Dosage Forms And Methods For Oral Administration Of Epothilones
US Patent:
RE40387, Jun 17, 2008
Filed:
Jun 9, 2005
Appl. No.:
11/149501
Inventors:
Rebanta Bandyopadhyay - Hyderabad, IN
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Marvin Barry Cohen - Newtown PA, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Marvin Barry Cohen - Newtown PA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/425, A61K 31/33, A61K 31/497, A61K 31/335
US Classification:
514365, 514183, 51425407, 514450
Abstract:
The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.
Parenteral Formulation For Epothilone Analogs
US Patent:
2006001, Jan 19, 2006
Filed:
Sep 14, 2005
Appl. No.:
11/226017
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Raghavan - Cranbury NJ, US
Sailesh Varia - Princeton Junction NJ, US
Timothy Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Raghavan - Cranbury NJ, US
Sailesh Varia - Princeton Junction NJ, US
International Classification:
A61K 31/427, A61K 9/00
US Classification:
424400000, 514365000
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.